Jupiter Neurosciences, Inc. (JUNS)

Jupiter Neurosciences will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$5.00 - $7.00
Shares Offered
2,500,000
Deal Size
$15.00M
Chart not available yet
Data will show when the stock starts trading.
Market Cap 55.05M
Revenue (ttm) 1.76M
Net Income (ttm) -2.06M
Shares Out 9.18M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About JUNS

Jupiter Neurosciences is a clinical stage research and development pharmaceutical company. The Company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation. The product, called JOTROL™, has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS as well as ALS which is in an early development stage. In the larger disease areas, we are primarily targeting Mild Cognitive Impairment/early Alzheimer’s disease ... [Read more...]

Industry Pharmaceuticals
Founded 2015
CEO Christer Rosén
Employees 5
Stock Exchange NASDAQ
Ticker Symbol JUNS
Full Company Profile

Financial Performance

Financial Statements

News

Neuro-inflammation biotech Jupiter Neurosciences revises terms, removes warrants ahead of $15 million IPO

Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, revised the terms for its upcoming IPO on Tuesday.

1 month ago - Renaissance Capital

Jupiter Neurosciences IPO Registration Document (S-1)

Jupiter Neurosciences, Inc. has filed to go public with an IPO on the NASDAQ.

11 months ago - SEC